Evidence map›Paper›PMID 30321631›Full record

ArticleHuman immunology2018

Report from the Killer-cell Immunoglobulin-like Receptors (KIR) component of the 17th International HLA and Immunogenetics Workshop.

Maneesh K Misra, Danillo G Augusto, Gonzalo Montero Martin, Neda Nemat-Gorgani, Jürgen Sauter, Jan A Hofmann, James A Traherne, Betsy González-Quezada, Clara Gorodezky, Will P Bultitude and 36 more

Abstract readConference Proceedings
PubMed Full text at PMC Publisher
In one paragraph

Article in Human immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. High-Resolution Characterization ofFrontiers in immunology · 2021
    Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

46 authors.

Maneesh K MisraDepartment of Neurology, University of California San Francisco, San Francisco, CA 94158, USA.
Danillo G AugustoDepartment of Neurology, University of California San Francisco, San Francisco, CA 94158, USA; Department of Genetics, Universidade Federal do Paraná, Curitiba, Brazil.
Gonzalo Montero MartinDepartment of Pathology, Stanford University School of Medicine, Stanford, CA 94304, USA.
Neda Nemat-GorganiDepartment of Structural Biology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Jürgen SauterDKMS gGmbH, Tübingen, Germany.
Jan A HofmannDKMS gGmbH, Tübingen, Germany.
James A TraherneDepartment of Pathology, University of Cambridge, Cambridge, UK.
Betsy González-QuezadaDepartment of Immunology and Immunogenetics, InDRE, Secretary of Health, Francisco P. Miranda #177, Colonia Lomas de Plateros, Del. Álvaro Obregón, CP 01480, Mexico City, Mexico; Fundación Comparte Vida, A.C. Galileo #92, Col. Polanco, Del. Miguel Hidalgo, CP 11550 Mexico City, Mexico.
Clara GorodezkyDepartment of Immunology and Immunogenetics, InDRE, Secretary of Health, Francisco P. Miranda #177, Colonia Lomas de Plateros, Del. Álvaro Obregón, CP 01480, Mexico City, Mexico; Fundación Comparte Vida, A.C. Galileo #92, Col. Polanco, Del. Miguel Hidalgo, CP 11550 Mexico City, Mexico.
Will P BultitudeAnthony Nolan Research Institute and UCL Cancer Institute, Royal Free Campus, Pond Street, London NW3 2QG, UK.
Wesley MarinDepartment of Neurology, University of California San Francisco, San Francisco, CA 94158, USA.
Cynthia Vierra-GreenCenter for International Blood and Marrow Transplant Research, Minneapolis, MN, USA.
Kirsten M AndersonDepartment of Neurology, University of California San Francisco, San Francisco, CA 94158, USA.
Antonio BalasHistocompatibility, Centro de Transfusión de la Comunidad de Madrid, Madrid, Spain.
Jose L Caro-OleasHistocompatibility and Immunogenetics, Banc de Sang i Teixits, Barcelona, Spain.
Elisa CisnerosImmunogenetics and Histocompatibility, Instituto de Investigación Sanitaria Puerta de Hierro, Madrid, Spain.
Francesco ColucciDepartment of Obstetrics and Gynaecology, National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge School of Clinical Medicine, Cambridge, UK; Centre for Trophoblast Research, University of Cambridge, Cambridge, UK.
Ravi DandekarDepartment of Neurology, University of California San Francisco, San Francisco, CA 94158, USA.
Sally M ElfishawiNational Cancer Institute, Cairo University, Cairo, Egypt.
Marcelo A Fernández-ViñaDepartment of Pathology, Stanford University School of Medicine, Stanford, CA 94304, USA.
Merhan FoudaNational Cancer Institute, Cairo University, Cairo, Egypt.
Rafael González-FernándezImmunology, Hospital Universitario Reina Sofía, Córdoba, Spain.
Arend GroßeDKMS Life Science Lab, Dresden, Germany.
Maria J Herrero-MataHistocompatibility and Immunogenetics, Banc de Sang i Teixits, Barcelona, Spain.
Sam Q HollenbachMacalester College, St. Paul, MN 55105, USA.
Steven G E MarshAnthony Nolan Research Institute and UCL Cancer Institute, Royal Free Campus, Pond Street, London NW3 2QG, UK.
Alex MentzerWellcome Trust Centre for Human Genetics, and Jenner Institute, University of Oxford, Oxford, UK.
Derek MiddletonRoyal Liverpool University Hospital, Liverpool L7 8XP, UK.
Ashley MoffettDepartment of Pathology, University of Cambridge, Cambridge, UK; Centre for Trophoblast Research, Cambridge, UK.
Miguel A Moreno-HidalgoHistocompatibility, Centro de Transfusión de la Comunidad de Madrid, Madrid, Spain.
Ghada I MossallamNational Cancer Institute, Cairo University, Cairo, Egypt.
Annettee NakimuliDepartment of Obstetrics and Gynecology, School of Medicine, Makerere University College of Health Sciences, Kampala, Uganda.
Jorge R OksenbergDepartment of Neurology, University of California San Francisco, San Francisco, CA 94158, USA.
Stephen J OppenheimerSchool of Anthropology and Museum Ethnography, University of Oxford, Oxford, UK.
Peter ParhamDepartment of Structural Biology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Maria-Luiza Petzl-ErlerDepartment of Genetics, Universidade Federal do Paraná, Curitiba, Brazil.
Dolores PlanellesHistocompatibility, Centro de Transfusión de la Comunidad Valenciana, Valencia, Spain.
Florentino Sánchez-GarcíaImmunology, Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de Gran Canaria, Spain.
Francisco Sánchez-GordoHistocompatibility, Centro de Transfusión de Málaga, Málaga, Spain.
Alexander H SchmidtDKMS gGmbH, Tübingen, Germany; DKMS Life Science Lab, Dresden, Germany.
John TrowsdaleDepartment of Pathology, University of Cambridge, Cambridge, UK.
Luciana B VargasDepartment of Genetics, Universidade Federal do Paraná, Curitiba, Brazil.
Jose L VicarioHistocompatibility, Centro de Transfusión de la Comunidad de Madrid, Madrid, Spain.
Carlos VilchesDepartment of Neurology, University of California San Francisco, San Francisco, CA 94158, USA.
Paul J NormanDepartment of Structural Biology, Stanford University School of Medicine, Stanford, CA 94305, USA; Division of Biomedical Informatics and Personalized Medicine, and Department of Immunology, University of Colorado, Denver, CO 80045, United States.
Jill A HollenbachDepartment of Neurology, University of California San Francisco, San Francisco, CA 94158, USA. Electronic address: jill.hollenbach@ucsf.edu.

Funding

Therapeutic Potential of Adaptive NK Cells in Cancer and TransplantationP01CA111412 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI FELICES, MARTIN · 2005 to 2025
$38.2M
Insights Into Immune-Related Diseases Born from Population GenomicsU01AI090905 · NIAID · UNIVERSITY OF COLORADO DENVER · PI Paul John Norman · 2010 to 2026
$10.9M
KIR association studies in neurological diseasesU19NS095774 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FERNANDEZ-VINA, MARCELO, OKSENBERG, JORGE R. · 2015 to 2019
$7.0M
BMI Bioinformatics Training GrantsT32GM067547 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HERNANDEZ, RYAN D. · 2003 to 2022
$6.6M
STRUCTURAL BIOLOGY OF HLA-A,B ANTIGENSR01AI017892 · NIAID · STANFORD UNIVERSITY · PI PARHAM, PETER R · 1985 to 2019
$6.1M
Integrated Exchange and Storage of Current- and Future-Generation Immunogenomic DataR01AI128775 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JILL Allison HOLLENBACH, STEVEN JOHN MACK · 2017 to 2026
$4.5M
Medical Research Council G0901682NCI NIH HHS P01 CA111412NIAID NIH HHS R01 AI017892NIAID NIH HHS R01 AI128775NIAID NIH HHS U01 AI090905NINDS NIH HHS U19 NS095774Wellcome Trust
6 · The paper itself

Abstract

The goals of the KIR component of the 17th International HLA and Immunogenetics Workshop (IHIW) were to encourage and educate researchers to begin analyzing KIR at allelic resolution, and to survey the nature and extent of KIR allelic diversity across human populations. To represent worldwide diversity, we analyzed 1269 individuals from ten populations, focusing on the most polymorphic KIR genes, which express receptors having three immunoglobulin (Ig)-like domains (KIR3DL1/S1, KIR3DL2 and KIR3DL3). We identified 13 novel alleles of KIR3DL1/S1, 13 of KIR3DL2 and 18 of KIR3DL3. Previously identified alleles, corresponding to 33 alleles of KIR3DL1/S1, 38 of KIR3DL2, and 43 of KIR3DL3, represented over 90% of the observed allele frequencies for these genes. In total we observed 37 KIR3DL1/S1 allotypes, 40 for KIR3DL2 and 44 for KIR3DL3. As KIR allotype diversity can affect NK cell function, this demonstrates potential for high functional diversity worldwide. Allelic variation further diversifies KIR haplotypes. We determined KIR3DL3 ∼ KIR3DL1/S1 ∼ KIR3DL2 haplotypes from five of the studied populations, and observed multiple population-specific haplotypes in each. This included 234 distinct haplotypes in European Americans, 191 in Ugandans, 35 in Papuans, 95 in Egyptians and 86 in Spanish populations. For another 35 populations, encompassing 642,105 individuals we focused on KIR3DL2 and identified another 375 novel alleles, with approximately half of them observed in more than one individual. The KIR allelic level data gathered from this project represents the most comprehensive summary of global KIR allelic diversity to date, and continued analysis will improve understanding of KIR allelic polymorphism in global populations. Further, the wealth of new data gathered in the course of this workshop component highlights the value of collaborative, community-based efforts in immunogenetics research, exemplified by the IHIW.

Indexed as

Multigene FamilyGene FrequencyGenetics, PopulationGenotypeHaplotypesHLA AntigensHumansImmunogeneticsProtein IsoformsReceptors, KIRSequence Analysis, DNAHLA AntigensProtein IsoformsReceptors, KIRKIR3DL1/S1KIR3DL2KIR3DL3

Identifiers

PMID30321631
PMCPMC6322681

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.